- Antisoma reports outcome of AS1413 phase III trial FierceBiotech
- PR_5_3_11 - Advanced Cancer Therapeutics
- Antisoma returns to profit - Financial Times
- Vadimezan - pedia
Antisoma reports outcome of AS1413 phase III trial FierceBiotech
Professor Cebon is the Medical Director of Cancer Services at the Olivia Newton John Cancer & Wellness Centre (ONJCWC) at Austin Health in Heidelberg VIC and the Director of the Ludw Institute for Cancer Research.
PR_5_3_11 - Advanced Cancer Therapeutics
He has recently been appointed as the Medical Director, Olivia Newton-John Cancer Research Institute, effective January 2015.
Antisoma returns to profit - Financial Times
CRISPR Therapeutics is led by a seasoned management team focused on translating CRISPR/Cas9 technology into transformative gene-based medicines for patients with serious diseases.
Vadimezan - pedia
Guildford, UK – 2 July 2015: Ergomed plc, (LSE: ERGO or ‘Ergomed’) a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces the appointment of Andrew Mackie as Chief Business Officer and to its Board as Executive Director, effective from 1 July 2015.
Rating: 99 / 100
Overall: 89 Rates